Glucagon-like-peptide-2 (glp-2) analogues

A method for treating anorexia in a patient in need thereof comprising administering to the patient a pharmaceutical composition formulated for parenteral administration comprising:

• (a) the glucagon-like peptide 2 (GLP-2) analogue [Gly2, Glu3, Leu10, Ala11, 24]hGLP-2-NH2 represented by the sequence:
• (SEQ ID NO:
• 4)
• HGEGSFSDELATILDNLAARDFIAWLIQTKITD-NH2,
• or a pharmaceutically acceptable salt or derivative thereof,
• (b) a pharmaceutically acceptable carrier comprising an aqueous carrier and the gelling agent hyaluronic acid;
• and
• (c) a solubility enhancer selected from Tween 20, Tween 80, Poloxamers, e.g., Pluronic F-68, Pluronic F-127, Brij 35, Brij 72, or cremophor EL,
• wherein the glucagon-like peptide 2 (GLP-2) analogue is administered in an amount sufficient to treat said anorexia.

A method of producing the GLP-2 analogue [Gly2, Thr7, Leu10, Lys11, Ala24]hGLP-2(1-30)-K6-NH2 represented by the sequence:

• (SEQ ID NO:
• 12)
• H-HGDGSFTDELKTILDNLAARDFIAWLIQTK6-NH2,
• said method comprising:
• (i) culturing host cells transformed with an expression vector comprising a nucleic acid sequence encoding the GLP-2 analogue under conditions suitable for expressing the GLP-2 analogue;
• and
• (ii) purifying the GLP-2 analogue thus produced.

A therapeutic kit comprising:

• (i) a cancer chemotherapy drug, and
• (ii) the glucagon-like peptide 2 (GLP-2) analogue [Gly2, Pro6, Leu10, Ala11, 16,24, 28]hGLP-2-NH2 represented by the sequence:
• (SEQ ID NO:
• 3)
• HGDGSPSDELATILDALAARDFIAWLIATKITD-NH2,
• or a pharmaceutically acceptable salt or derivative thereof.